Current Report Filing (8-k)
June 05 2018 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 1, 2018
MEDICINOVA, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-33185
|
|
33-0927979
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
4275 EXECUTIVE SQUARE,
SUITE 300, LA JOLLA, CA
|
|
92037
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (858)
373-1500
Check the
appropriate box below if the
Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2.
below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth
company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On June 1, 2018, Ryan Selhorn resigned as the Chief Financial Officer of the MediciNova, Inc. (the Company). Mr. Selhorn had served as
the Companys Chief Financial Officer through a services agreement (the Services Agreement) between the Company and the accounting services firm Signature Analytics San Diego LLC (Signature Analytics). Mr. Selhorn
previously resigned from Signature Analytics.
Effective June 1, 2018, the Board of Directors of the Company appointed Carla Reyes of Signature
Analytics to serve as Chief Financial Officer and principal financial officer of the Company. In connection with Ms. Reyes appointment as Chief Financial Officer, on the same date, the Company entered into an amendment to the Services
Agreement with Signature Analytics for the provision of Ms. Reyes services. Under the Services Agreement, as amended, the Company will continue to pay
pre-approved
hourly rates for the services
provided under the Services Agreement. The current term of the Services Agreement, as amended, will expire on March 31, 2019, subject to earlier termination according to its terms.
Ms. Reyes, age 46, joined Signature Analytics in May 2018. From August 2013 to May 2018, Ms. Reyes served as Accounting Manager at Rady
Childrens
Hospital-San
Diego, where she was responsible for financial reporting, grants and contracts, and philanthropy accounting. Prior to this, Ms. Reyes served as Senior Manager of Business
Processes at Cricket Communications, a wireless service provider, from May 2009 to August 2013. Earlier in her career, Ms. Reyes served in accounting and public reporting roles at SAIC, NextWave and Quest Software. Ms. Reyes received a
Bachelor of Accountancy and an MBA from the University of San Diego.
There are no family relationships between Ms. Reyes and any of the
Companys other directors or executive officers, and Ms. Reyes does not have any direct or indirect material interests in any transaction required to be disclosed pursuant to Item 404(a) of Regulation
S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MEDICINOVA, INC.
|
|
|
|
|
DATE: June 5, 2018
|
|
|
|
By:
|
|
/s/ Yuichi Iwaki
|
|
|
|
|
|
|
Yuichi Iwaki, M.D., Ph.D.
|
|
|
|
|
|
|
Chief Executive Officer
|
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Apr 2023 to Apr 2024